Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sopharma Trading AD's Enterprise Value is €271 Mil.
Sopharma Trading AD's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €3 Mil. Therefore, Sopharma Trading AD's EV-to-FCF for today is 89.06.
The historical rank and industry rank for Sopharma Trading AD's EV-to-FCF or its related term are showing as below:
XBUL:SFT'
s EV-to-FCF Range Over the Past 10 Years
Min: -52.24 Med: -3.12 Max: 1056.61
Current: 87.49
During the past 13 years, the highest EV-to-FCF of Sopharma Trading AD was 1056.61. The lowest was -52.24. And the median was -3.12.
XBUL:SFT's EV-to-FCF is ranked worse than 88.57% of 70
companies
in the Medical Distribution industry
Industry Median: 16.14
vs XBUL:SFT: 87.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sopharma Trading AD (XBUL:SFT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sopharma Trading AD's PE Ratio (TTM) for today is calculated as:
Sopharma Trading AD's share price for today is €2.96.
Sopharma Trading AD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.749.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sopharma Trading AD EV-to-FCF Related Terms
Sopharma Trading AD EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma Trading AD's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's EV-to-FCF falls into.
Sopharma Trading AD's current Enterprise Value is €271 Mil.
Sopharma Trading AD's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (XBUL:SFT) has a EV-to-FCF of 89.06 as of Aug. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sopharma Trading AD and its competitors. According to the industry distribution chart, Sopharma Trading AD ranks #62 out of 70 companies in the Medical Distribution industry, placing it in the top 88.6%.
Is Sopharma Trading AD's EV-to-FCF too high?
Sopharma Trading AD's current EV-to-FCF is 89.06. The Medical Distribution industry median EV-to-FCF is 16.14. Sopharma Trading AD's value of 89.06 is 451.8% above this industry median. Based on the distribution chart, Sopharma Trading AD ranks #62 out of 70 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #62 out of 70 companies for EV-to-FCF. This places Sopharma Trading AD in the lower half of its industry. The industry median EV-to-FCF is 16.14. Sopharma Trading AD's value of 89.06 is 451.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 16.14, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current EV-to-FCF of 89.06 is 451.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 16.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current EV-to-FCF is 89.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.73, compared to a current price of €2.96 — trading 61.7% below its estimated fair value. The current EV-to-FCF is 89.06 and 451.8% above the Medical Distribution industry median of 16.14. Sopharma Trading AD's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current EV-to-FCF is 89.06 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.96 is trading 61.7% below its estimated GF Value™ of €7.73.
GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.
Key valuation signals for XBUL:SFT:
EV-to-FCF: 89.06
GF Value™: €7.73 vs. price of €2.96 (61.7% below fair value)
Industry Position: 451.8% above the Medical Distribution median (#62 of 70)
No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
78GF Score
Get the complete analysis for XBUL:SFT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFT has been successfully added to your 
